{"created":"2023-05-15T14:48:10.338594+00:00","id":66014,"links":{},"metadata":{"_buckets":{"deposit":"1a3c2c55-8379-4618-b019-039379874416"},"_deposit":{"created_by":1,"id":"66014","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"66014"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00066014","sets":["10:29"]},"author_link":["650063","650064","650067","650062","650066","650065"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2016-11-04","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Peritoneal metastasis of gastric cancer (PMGC) has extremely poor prognosis, however, there is no effective therapeutics has been established. About 20% of GC is reported as HER2-overexpressed (HER2+), and trastuzumab, a humanized anti-HER2 monoclonal antibody, has been used for the treatment for HER2+ PMGC. Radioimmunotherapy (RIT) has huge advantages in targeting metastatic cancer and the application of alpha-emitter into RIT is getting higher attention. Astatine 211 (<SUP>211</SUP>At) is one of the useful alpha-emitter. In this study, we investigated the cell cytotoxicity and therapeutic efficacy of RIT with <SUP>211</SUP>At-trastuzumab against of HER2+ PMGC both in vitro and in vivo. We will discuss the possibility of alpha-RIT with <SUP>211</SUP>At-trastuzumab as a new effective therapeutics for HER2+ PMGC.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第56回日本核医学会学術集会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"李, 惠子"}],"nameIdentifiers":[{"nameIdentifier":"650062","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"諸越, 幸恵"}],"nameIdentifiers":[{"nameIdentifier":"650063","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"長谷川, 純崇"}],"nameIdentifiers":[{"nameIdentifier":"650064","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"李 惠子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"650065","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"諸越 幸恵","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"650066","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"長谷川 純崇","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"650067","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"HER2高発現胃がん腹膜播種に対するα線放出核種211Atを用いた放射免疫療法","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"HER2高発現胃がん腹膜播種に対するα線放出核種211Atを用いた放射免疫療法"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2016-11-09"},"publish_date":"2016-11-09","publish_status":"0","recid":"66014","relation_version_is_last":true,"title":["HER2高発現胃がん腹膜播種に対するα線放出核種211Atを用いた放射免疫療法"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T20:53:41.026448+00:00"}